Sickle-Cell Disease — Clinical Documentation Guide (2026)

🔍 Definition

Sickle-cell disease (SCD) is a group of inherited hemoglobin disorders caused by a point mutation in the beta-globin gene (HBB) that produces abnormal hemoglobin S (HbS). When HbS is present in sufficient quantity, red blood cells polymerize under low-oxygen conditions, deforming into rigid, sickle-shaped cells that obstruct microvascular blood flow, causing vaso-occlusion, hemolytic anemia, and multi-organ damage. Per the National Heart, Lung, and Blood Institute (NHLBI), sickle-cell disease affects approximately 100,000 Americans — predominantly those of African, Mediterranean, Middle Eastern, and South Asian descent — and represents the most common serious inherited blood disorder in the United States.

The most severe and common genotype is homozygous HbSS (sickle-cell anemia, historically called "Hb-SS disease"). Other clinically significant genotypes include HbSC disease, HbS-β⁰ thalassemia (functionally as severe as HbSS), and HbS-β⁺ thalassemia (milder course). Each genotype carries distinct ICD-10-CM coding implications under the FY2026 D57.xx category.

For ICD-10-CM purposes, SCD maps to CMS ICD-10-CM category D57 (Sickle-cell disorders), with subcategories capturing genotype, crisis type, and specific acute or chronic complications. Precise code selection requires documentation of the genotype (HbSS, HbSC, HbS-β⁰, HbS-β⁺, other), current crisis status, and the specific complication driving the encounter.

🗂️ Alternative Terminology

Multiple clinical and lay terms are used interchangeably in documentation. Coders must map these to the correct D57 subcategory.

🩺 Signs & Symptoms

Clinical presentation varies by genotype, age, and crisis type. Documentation must be specific enough to support the most granular ICD-10-CM subcategory available.

• Vaso-occlusive crisis (VOC/pain crisis): Severe, acute pain in bones, chest, abdomen, or joints; fever; tachycardia. Most common reason for ED visits and hospitalizations. Per NHLBI guidelines, VOC accounts for over 90% of SCD hospitalizations.
• Acute chest syndrome (ACS): New pulmonary infiltrate on chest X-ray with fever ≥38.5°C, respiratory symptoms (chest pain, cough, hypoxia, tachypnea). Second most common cause of hospitalization; leading cause of death in SCD.
• Splenic sequestration: Rapid spleen enlargement with acute fall in hemoglobin (>2 g/dL), thrombocytopenia, left upper quadrant pain; hypovolemic shock possible. Primarily in children before autosplenectomy.
• Cerebral vascular involvement: Acute stroke (ischemic or hemorrhagic), transient ischemic attack, or silent cerebral infarct detected on MRI. Children with HbSS have up to 11% lifetime stroke risk without prophylaxis.
• Dactylitis: Symmetric swelling and pain in hands/feet; often the presenting crisis in infants aged 6–24 months.
• Chronic hemolytic anemia: Baseline hemoglobin 6–9 g/dL (HbSS); jaundice; cholelithiasis (pigment stones); elevated LDH, indirect bilirubin.
• Chronic organ damage: Nephropathy (hematuria, proteinuria, CKD), avascular necrosis (femoral/humeral head), pulmonary hypertension, leg ulcers, retinopathy, priapism (males), cardiomegaly.
• Aplastic crisis: Sudden drop in hemoglobin due to Parvovirus B19 infection suppressing erythropoiesis.

🧭 Differential Diagnosis

Several conditions share features with SCD or its acute complications. Clinical context and laboratory findings differentiate them.

📋 Clinical Indicators for Coders/CDI

The following clinical findings support documentation and coding specificity for sickle-cell disease. CDI specialists should review these indicators against the medical record before finalizing code assignment per AHIMA and ACDIS standards.

🦴 Anatomy & Pathophysiology

Sickle-cell disease results from a single nucleotide substitution (glutamic acid → valine) at codon 6 of the beta-globin gene on chromosome 11. This produces hemoglobin S (HbS), which polymerizes under hypoxic conditions, creating long rigid chains that deform erythrocytes into the characteristic crescent shape.

Vaso-occlusion cascade: Sickled cells are rigid, dense, and adhesive. They adhere to vascular endothelium via P-selectin/E-selectin pathways (target of crizanlizumab) and interact with activated leukocytes and platelets, creating a "tangled" obstruction in postcapillary venules. The resulting ischemia triggers inflammatory cytokine release, oxidative stress, and endothelial injury, amplifying the cycle of sickling and reperfusion injury.

Hemolysis: Sickled RBCs are fragile, with a lifespan of 10–20 days (vs. 120 days for normal RBCs). Intravascular hemolysis releases free hemoglobin and arginase, depleting nitric oxide (NO) — a potent vasodilator. Chronic NO depletion contributes to pulmonary hypertension, priapism, leg ulcers, and stroke risk. This explains why fetal hemoglobin (HbF) induction — the mechanism of both hydroxyurea and Casgevy gene therapy — reduces complications: HbF does not participate in HbS polymerization.

Organ damage progression:

• Spleen: Repetitive infarction leads to autosplenectomy in HbSS by age 5, causing functional asplenia and dramatically increased susceptibility to encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Salmonella).
• Kidneys: Medullary hypoxia and repeated sickling cause sickle cell nephropathy — early hematuria/proteinuria, loss of concentrating ability, progressing to CKD and ESRD in 4–18% of patients.
• Brain: Cerebral vasculopathy (Moyamoya-pattern) from chronic sickle injury to large vessels; transcranial Doppler (TCD) screening identifies children at highest stroke risk. Per NHLBI, chronic transfusion therapy reduces stroke risk by ~90% in high-TCD children.
• Bone: Intramedullary sickling causes avascular necrosis (most commonly femoral head and humeral head). Bone marrow expansion due to chronic hemolysis causes characteristic "hair-on-end" skull radiograph findings.
• Lungs: ACS is both a cause and consequence of fat embolism, infection, and in-situ pulmonary sickling. Recurrent ACS leads to pulmonary fibrosis and pulmonary hypertension (I27.2x).

💊 Medication Impact / Treatment

Medication documentation directly affects ICD-10-CM code assignment, CPT coding, HCPCS billing, and risk adjustment. The following agents are relevant to FY2026 encounters.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides